

Cancer SLC43A2 alters T cell methionine metabolism and

Nature

585, 277-282

DOI: [10.1038/s41586-020-2682-1](https://doi.org/10.1038/s41586-020-2682-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Humoral immune responses: Unsung heroes of the war on cancer. <i>Seminars in Immunology</i> , 2020, 49, 101419.	2.7	11
2	A Tug-of-War Over Methionine. <i>Cell Metabolism</i> , 2020, 32, 699-701.	7.2	1
3	Metabolic interventions: A new insight into the cancer immunotherapy. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108659.	1.4	8
4	Metabolic traits ruling the specificity of the immune response in different cancer types. <i>Current Opinion in Biotechnology</i> , 2021, 68, 124-143.	3.3	4
5	The Bidirectional Relationship Between Cancer Epigenetics and Metabolism. <i>Annual Review of Cancer Biology</i> , 2021, 5, 235-257.	2.3	28
6	Immunometabolism in the Tumor Microenvironment. <i>Annual Review of Cancer Biology</i> , 2021, 5, 137-159.	2.3	28
7	Mitochondrial and Metabolic Pathways Regulate Nuclear Gene Expression to Control Differentiation, Stem Cell Function, and Immune Response in Leukemia. <i>Cancer Discovery</i> , 2021, 11, 1052-1066.	7.7	24
8	Histone methyltransferase DOT1L controls state-specific identity during B cell differentiation. <i>EMBO Reports</i> , 2021, 22, e51184.	2.0	27
9	Role of Methylation in Pro- and Anti-Cancer Immunity. <i>Cancers</i> , 2021, 13, 545.	1.7	53
10	Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. <i>Protein and Cell</i> , 2021, 12, 240-260.	4.8	57
11	Epigenetic Mechanisms beyond Tumour-Stroma Crosstalk. <i>Cancers</i> , 2021, 13, 914.	1.7	10
12	Emerging roles of the solute carrier family in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e356.	1.7	29
13	Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 255-260.	1.6	16
14	Autophagy in tumour immunity and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 281-297.	12.8	185
15	Tissue-resident memory T cells in tumor immunity and immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	94
16	Metabolic Control of Memory T-Cell Generation and Stemness. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037770.	2.3	6
17	T cell metabolism in homeostasis and cancer immunity. <i>Current Opinion in Biotechnology</i> , 2021, 68, 240-250.	3.3	20
18	Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 640369.	2.2	26

#	ARTICLE	IF	CITATIONS
19	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
20	Amino acids and RagD potentiate mTORC1 activation in CD8 ⁺ T cells to confer antitumor immunity. <i>Frontiers in Immunology</i> , 2021, 9, e002137.		13
21	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. <i>Cancer Cell</i> , 2021, 39, 480-493.e6.	7.7	71
22	Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications. <i>Frontiers in Immunology</i> , 2021, 12, 641883.	2.2	10
23	A guide to interrogating immunometabolism. <i>Nature Reviews Immunology</i> , 2021, 21, 637-652.	10.6	87
24	Abnormal arginine metabolism is associated with prognosis in patients of gastric cancer. <i>Translational Cancer Research</i> , 2021, 10, 2451-2469.	0.4	8
25	How metabolism bridles cytotoxic CD8 ⁺ T cells through epigenetic modifications. <i>Trends in Immunology</i> , 2021, 42, 401-417.	2.9	18
26	Metabolic reprogramming and epigenetic modifications on the path to cancer. <i>Protein and Cell</i> , 2022, 13, 877-919.	4.8	179
27	CD8 ⁺ T cell metabolism in infection and cancer. <i>Nature Reviews Immunology</i> , 2021, 21, 718-738.	10.6	181
28	Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth. <i>Stem Cells International</i> , 2021, 2021, 1-17.	1.2	14
29	Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. <i>Journal of Hematology and Oncology</i> , 2021, 14, 98.	6.9	173
30	Amino Acid Depletion Therapies: Starving Cancer Cells to Death. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 367-381.	3.1	121
31	The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations. <i>Frontiers in Immunology</i> , 2021, 12, 717540.	2.2	5
32	Cancer metabolism: looking forward. <i>Nature Reviews Cancer</i> , 2021, 21, 669-680.	12.8	676
33	SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/ β -catenin/MYC/HMGCS2 axis. <i>British Journal of Cancer</i> , 2021, 125, 865-876.	2.9	33
34	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. <i>Cellular and Molecular Immunology</i> , 2022, 19, 46-58.	4.8	39
35	Impact of One-Carbon Metabolism-Driving Epitranscriptome as a Therapeutic Target for Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7278.	1.8	5
36	Regulation of the epigenetic landscape by immune cell oxidants. <i>Free Radical Biology and Medicine</i> , 2021, 170, 131-149.	1.3	8

#	ARTICLE	IF	CITATIONS
37	MYC Ran Up the Clock: The Complex Interplay between MYC and the Molecular Circadian Clock in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7761.	1.8	16
38	NAD ⁺ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. <i>Cell Reports</i> , 2021, 36, 109516.	2.9	50
39	Another Weak Link in the Electron Transport Chain: Variants in SUCLG2 and Risk for Pheochromocytoma and Paraganglioma. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	1
40	Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. <i>Seminars in Immunology</i> , 2021, 52, 101485.	2.7	24
41	A planetary health perspective on synthetic methionine. <i>Lancet Planetary Health</i> , The, 2021, 5, e560-e569.	5.1	21
42	IFN γ signaling integrity in colorectal cancer immunity and immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 23-32.	4.8	57
43	Essential amino acid metabolism-related molecular classification in triple-negative breast cancer. <i>Epigenomics</i> , 2021, 13, 1247-1268.	1.0	3
44	Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids. <i>Trends in Cancer</i> , 2021, 7, 682-699.	3.8	56
45	Regulation of antitumor immunity by inflammation-induced epigenetic alterations. <i>Cellular and Molecular Immunology</i> , 2022, 19, 59-66.	4.8	29
47	Epigenomic links from metabolism to methionine and chromatin architecture. <i>Current Opinion in Chemical Biology</i> , 2021, 63, 11-18.	2.8	5
48	Moonlighting functions of metabolic enzymes and metabolites in cancer. <i>Molecular Cell</i> , 2021, 81, 3760-3774.	4.5	65
49	Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10268.	1.8	11
50	L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy. <i>Journal of Pharmacological Sciences</i> , 2022, 148, 31-40.	1.1	15
51	Solute carrier transporters: emerging central players in tumour immunotherapy. <i>Trends in Cell Biology</i> , 2022, 32, 186-201.	3.6	21
52	Amino Acids and Their Transporters in T Cell Immunity and Cancer Therapy. <i>Molecular Cell</i> , 2020, 80, 384-395.	4.5	128
53	Control of T-Cell Activation and Signaling by Amino-Acid Catabolizing Enzymes. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 613416.	1.8	16
54	Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment. , 2021, 9, e003217.		29
55	SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential. <i>EBioMedicine</i> , 2021, 72, 103614.	2.7	24

#	ARTICLE	IF	CITATIONS
56	RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 1018-1038.	5.7	11
57	Metabolic regulation of the cancer-immunity cycle. <i>Trends in Immunology</i> , 2021, 42, 975-993.	2.9	28
58	H3K36 trimethylation-mediated biological functions in cancer. <i>Clinical Epigenetics</i> , 2021, 13, 199.	1.8	25
59	Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited. <i>Cancer Immunology Research</i> , 2021, 9, 1373-1382.	1.6	33
60	Metabolic Fuel for Epigenetic: Nuclear Production Meets Local Consumption. <i>Frontiers in Genetics</i> , 2021, 12, 768996.	1.1	18
61	Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy. <i>Cancers</i> , 2021, 13, 5912.	1.7	13
62	Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12168.	5.5	19
63	Cancer metabolism and tumor microenvironment: fostering each other?. <i>Science China Life Sciences</i> , 2022, 65, 236-279.	2.3	68
64	pH-Regulating Nanoplatfor for the "Double Channel Chase" of Tumor Cells by the Synergistic Cascade between Chlorine Treatment and Methionine-Depletion Starvation Therapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 54690-54705.	4.0	10
65	Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. <i>Frontiers in Oncology</i> , 2021, 11, 759015.	1.3	13
66	Identification and Validation of an 6-Metabolism-Related Gene Signature and Its Correlation With Immune Checkpoint in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 783934.	1.3	3
67	The CBL-LSD1-CXCL8 axis regulates methionine metabolism in glioma. <i>Cytokine</i> , 2022, 151, 155789.	1.4	2
68	Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 27.	7.9	35
69	Protein synthesis, degradation, and energy metabolism in T cell immunity. <i>Cellular and Molecular Immunology</i> , 2022, 19, 303-315.	4.8	38
70	Metabolic adaptation of lymphocytes in immunity and disease. <i>Immunity</i> , 2022, 55, 14-30.	6.6	91
71	The Interplay Between Epigenetic Regulation and CD8+ T Cell Differentiation/Exhaustion for T Cell Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 783227.	1.8	11
72	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 809761.	2.2	29
73	Amino Acid Metabolism in Cancer Drug Resistance. <i>Cells</i> , 2022, 11, 140.	1.8	40

#	ARTICLE	IF	CITATIONS
74	Microenvironmental influences on T cell immunity in cancer and inflammation. Cellular and Molecular Immunology, 2022, 19, 316-326.	4.8	38
76	Tumor microenvironment metabolites directing T cell differentiation and function. Trends in Immunology, 2022, 43, 132-147.	2.9	18
77	Regulation of Ferroptosis by Amino Acid Metabolism in Cancer. International Journal of Biological Sciences, 2022, 18, 1695-1705.	2.6	23
78	Global change of microRNA expression induced by vitamin C treatment on immature boar Sertoli cells. Theriogenology, 2022, 183, 1-9.	0.9	3
79	Connections between metabolism and epigenetic modifications in cancer. Medical Review, 2021, 1, 199-221.	0.3	7
80	Pan-Cancer Indicators of Long-Term Survival Benefits After Immune Checkpoint Inhibitor Therapy. SSRN Electronic Journal, 0, , .	0.4	0
81	Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment. Frontiers in Immunology, 2022, 13, 845923.	2.2	11
82	Immunometabolism at the intersection of metabolic signaling, cell fate, and systems immunology. Cellular and Molecular Immunology, 2022, 19, 299-302.	4.8	19
83	The critical function of metabolic reprogramming in cancer metastasis. Aging and Cancer, 2022, 3, 20-43.	0.5	4
84	Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell, 2022, 40, 185-200.e6.	7.7	97
85	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nature Communications, 2022, 13, 866.	5.8	51
86	DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway. Oncolmmunology, 2022, 11, 2052640.	2.1	4
87	Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy. Pharmaceutics, 2022, 14, 734.	2.0	1
88	Metabolic Regulation of CD8 ⁺ T Cells: From Mechanism to Therapy. Antioxidants and Redox Signaling, 2022, 37, 1234-1253.	2.5	5
89	Essential amino acids deprivation is a potential strategy for breast cancer treatment. Breast, 2022, 62, 152-161.	0.9	6
90	Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Reports, 2022, 39, 110609.	2.9	46
91	Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. IScience, 2022, 25, 104162.	1.9	14
92	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Molecular Cancer, 2021, 20, 171.	7.9	106

#	ARTICLE	IF	CITATIONS
93	Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. <i>Cancers</i> , 2022, 14, 183.	1.7	8
94	The Role of Methyl Donors of the Methionine Cycle in Gastrointestinal Infection and Inflammation. <i>Healthcare (Switzerland)</i> , 2022, 10, 61.	1.0	5
95	Cancer metabolism and dietary interventions. <i>Cancer Biology and Medicine</i> , 2021, , .	1.4	9
96	Function of BCLAF1 in human disease (Review). <i>Oncology Letters</i> , 2021, 23, 58.	0.8	16
97	Impact of cancer cell-intrinsic features on neutrophil behavior. <i>Seminars in Immunology</i> , 2021, 57, 101546.	2.7	9
98	The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. <i>Cell Metabolism</i> , 2022, 34, 731-746.e9.	7.2	63
99	Dissecting the heterogeneity of exhausted T cells at the molecular level. <i>International Immunology</i> , 2022, 34, 547-553.	1.8	2
100	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2022, 40, 45-74.	9.5	122
101	Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1303-1324.	2.5	1
103	Chemoprevention of Lung Cancer with a Combination of Mitochondria-Targeted Compounds. <i>Cancers</i> , 2022, 14, 2538.	1.7	6
106	Blockade LAT1 Mediates Methionine Metabolism to Overcome Oxaliplatin Resistance under Hypoxia in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2551.	1.7	2
107	Impact of tumor microenvironment on adoptive T cell transfer activity. <i>International Review of Cell and Molecular Biology</i> , 2022, , 1-31.	1.6	8
108	Targeting the methionine~methionine adenosyl transferase 2A~S-adenosyl methionine axis for cancer therapy. <i>Current Opinion in Oncology</i> , 0, Publish Ahead of Print, .	1.1	6
109	Methionine deficiency facilitates antitumour immunity by altering m ⁶ A methylation of immune checkpoint transcripts. <i>Gut</i> , 2023, 72, 501-511.	6.1	51
110	Inflammation: the incubator of the tumor microenvironment. <i>Trends in Cancer</i> , 2022, 8, 901-914.	3.8	57
111	Regulation of immune cell metabolism in health and disease: Special focus on T and B cell subsets. <i>Cell Biology International</i> , 2022, 46, 1729-1746.	1.4	7
112	Analysis of the Prognostic Significance and Immune Infiltration of the Amino Acid Metabolism-Related Genes in Colon Adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
113	Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
114	Methionine cycle-dependent regulation of T cells in cancer immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
115	Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer. <i>Cancer Discovery</i> , 2022, 12, 2258-2279.	7.7	18
116	Site-specific decreases in DNA methylation in replicating cells following exposure to oxidative stress. <i>Human Molecular Genetics</i> , 2023, 32, 632-648.	1.4	0
117	Glutamine is essential for overcoming the immunosuppressive microenvironment in malignant salivary gland tumors. <i>Theranostics</i> , 2022, 12, 6038-6056.	4.6	1
118	Keep a watchful eye on methionine adenosyltransferases, novel therapeutic opportunities for hepatobiliary and pancreatic tumours. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188793.	3.3	4
119	Lactate metabolism in human health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	196
120	Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	17
121	Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. <i>Cancer Research</i> , 2022, 82, 4386-4399.	0.4	5
122	Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
123	Polycomb Directed Cell Fate Decisions in Development and Cancer. <i>Epigenomes</i> , 2022, 6, 28.	0.8	8
124	Introduction: Redefining T-cell Exhaustion Special Issue. <i>International Immunology</i> , 2022, 34, 545-546.	1.8	0
125	Autophagy in Cancer Immunotherapy. <i>Cells</i> , 2022, 11, 2996.	1.8	17
126	MTAP deficiency contributes to immune landscape remodeling and tumor evasion. <i>Immunology</i> , 0, , .	2.0	1
127	Metabolic and epigenetic orchestration of (CAR) T cell fate and function. <i>Cancer Letters</i> , 2022, 550, 215948.	3.2	5
128	Metabolic communication in the tumourâ€™ immune microenvironment. <i>Nature Cell Biology</i> , 2022, 24, 1574-1583.	4.6	65
129	Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity. <i>Cells</i> , 2022, 11, 3103.	1.8	6
130	Comprehensive Molecular Analyses of an SLC Family-Based Model in Stomach Adenocarcinoma. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	1
131	Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1015-1027.	2.0	7

#	ARTICLE	IF	CITATIONS
132	Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion. <i>Nature Communications</i> , 2022, 13, .	5.8	24
133	Serum Metabolomic Profiling in Aging Mice Using Liquid Chromatography–Mass Spectrometry. <i>Biomolecules</i> , 2022, 12, 1594.	1.8	6
134	From thymus to tissues and tumors: A review of T-cell biology. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 81-97.	1.5	14
135	Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	14
136	Metabolic regulation by p53 prevents R-loop-associated genomic instability. <i>Cell Reports</i> , 2022, 41, 111568.	2.9	13
137	Progress in research on the role of amino acid metabolic reprogramming in tumour therapy: A review. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113923.	2.5	7
138	CD8+ T cell metabolic changes in breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166565.	1.8	0
139	Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies. <i>Cell Metabolism</i> , 2022, 34, 1999-2017.e10.	7.2	22
140	Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
141	DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
142	Metabolic determinants of tumour initiation. <i>Nature Reviews Endocrinology</i> , 2023, 19, 134-150.	4.3	16
143	Identification of an Amino Acid Metabolism-Related Gene Signature for Predicting Prognosis in Lung Adenocarcinoma. <i>Genes</i> , 2022, 13, 2295.	1.0	1
144	Methionine Metabolism Is Down-Regulated in Heart of Long-Lived Mammals. <i>Biology</i> , 2022, 11, 1821.	1.3	2
145	Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. <i>Cancers</i> , 2023, 15, 48.	1.7	4
146	High-throughput in situ perturbation of metabolite levels in the tumor micro-environment reveals favorable metabolic condition for increased fitness of infiltrated T-cells. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
147	Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3
148	Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
149	Effects of metabolic cancer therapy on tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5

#	ARTICLE	IF	CITATIONS
150	Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer. <i>Cell Metabolism</i> , 2023, 35, 134-149.e6.	7.2	23
151	Manipulation of Amino Acid Levels with Artificial Diets Induces a Marked Anticancer Activity in Mice with Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16132.	1.8	2
152	Immune Cell Metabolism and Immuno-Oncology. <i>Annual Review of Cancer Biology</i> , 2023, 7, 93-110.	2.3	4
153	Metabolic adaptations of cancer in extreme tumor microenvironments. <i>Cancer Science</i> , 2023, 114, 1200-1207.	1.7	2
154	Single-cell and spatial analyses reveal the association between gene expression of glutamine synthetase with the immunosuppressive phenotype of <scp>APOE</scp>+<scp>CTSZ</scp>+<scp>TAM</scp> in cancers. <i>Molecular Oncology</i> , 2023, 17, 611-628.	2.1	6
155	Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	14
156	Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy. <i>Biomedicines</i> , 2023, 11, 169.	1.4	0
157	Upregulation of SLC12A3 and SLC12A9 Mediated by the HCP5/miR-140-5p Axis Confers Aggressiveness and Unfavorable Prognosis in Uveal Melanoma. <i>Laboratory Investigation</i> , 2023, 103, 100022.	1.7	3
158	Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity. <i>Immunity</i> , 2023, 56, 32-42.	6.6	33
159	Profiling the Epigenetic Landscape of the Tumor Microenvironment Using Chromatin Immunoprecipitation Sequencing. <i>Methods in Molecular Biology</i> , 2023, , 313-348.	0.4	0
160	Labeling Assembly of Hydrophilic Methionine into Nanoparticle for Mild Heat Mediated Immunometabolic Therapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	2
161	S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas. <i>Neoplasia</i> , 2023, 36, 100874.	2.3	3
162	T-Cell Exhaustion in Cancers. , 2023, , 1-29.		0
163	Epigenetically programmed resistance to chemo- and immuno-therapies. <i>Advances in Cancer Research</i> , 2023, , 41-71.	1.9	0
164	Manipulation of metabolic pathways to promote stem-like and memory T cell phenotypes for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
165	Regulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses. <i>Journal of Immunology</i> , 2023, 210, 869-879.	0.4	2
166	Cancer metabolism within tumor microenvironments. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2023, 1867, 130330.	1.1	7
169	Double-edged roles of IFN γ in tumor elimination and immune escape. <i>Journal of Pancreatology</i> , 2023, 6, 8-17.	0.3	1

#	ARTICLE	IF	CITATIONS
170	Hepatic phosphatidylcholine catabolism driven by PNPLA7 and PNPLA8 supplies endogenous choline to replenish the methionine cycle with methyl groups. <i>Cell Reports</i> , 2023, 42, 111940.	2.9	9
171	Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness. <i>Nature Metabolism</i> , 2023, 5, 314-330.	5.1	24
172	Nutrient transporters: connecting cancer metabolism to therapeutic opportunities. <i>Oncogene</i> , 2023, 42, 711-724.	2.6	5
173	Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	19
174	Metabolic programming and immune suppression in the tumor microenvironment. <i>Cancer Cell</i> , 2023, 41, 421-433.	7.7	70
175	Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy. , 2023, 11, e005986.		2
176	A Zeb1/MtCK1 metabolic axis controls osteoclast activation and skeletal remodeling. <i>EMBO Journal</i> , 2023, 42, .	3.5	3
177	What is cancer metabolism?. <i>Cell</i> , 2023, 186, 1670-1688.	13.5	41
178	m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion. <i>Molecular Cancer</i> , 2023, 22, .	7.9	14
179	The Lysophospholipase PNPLA7 Controls Hepatic Choline and Methionine Metabolism. <i>Biomolecules</i> , 2023, 13, 471.	1.8	4
180	Proteolytic regulation of a galectin-3/Lrp1 axis controls osteoclast-mediated bone resorption. <i>Journal of Cell Biology</i> , 2023, 222, .	2.3	5
183	The metabolic cross-talk between cancer and T cells. <i>Trends in Biochemical Sciences</i> , 2023, 48, 597-609.	3.7	1
216	Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment. <i>Amino Acids</i> , 2023, 55, 1213-1222.	1.2	3
218	Methylation across the central dogma in health and diseases: new therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7
220	Amino acid metabolism in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	14
221	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	1.5	0
224	Immunometabolism: a new dimension in immunotherapy resistance. <i>Frontiers of Medicine</i> , 2023, 17, 585-616.	1.5	0
231	Metabolic control of cancer metastasis: role of amino acids at secondary organ sites. <i>Oncogene</i> , 2023, 42, 3447-3456.	2.6	0

#	ARTICLE	IF	CITATIONS
235	Vitamin B5 supports MYC oncogenic metabolism and tumor progression in breast cancer. Nature Metabolism, 2023, 5, 1870-1886.	5.1	3